|
BACKGROUND: Hepatocellular carcinoma is our country and the world one of the most common malignancies, ranking the country second in cancer mortality and increasing year by year. Because of its high degree of malignancy of all cancers, the development of faster, shorter survival time, treatment more difficult, has been recognized as a hazard to human life and health of one of the most serious malignancies. In recent decades, with the liver basic and clinical research, the continual emergence of new therapies and clinical applications, especially small HCC effective treatment significantly improved the survival rate of liver cancer, the prognosis has improved over the previous , but still need to be further improved. Currently, liver cancer treatment, although many, but the cancer recurrence rate is still high, even small hepatocellular carcinoma, the 5-year recurrence rate is still 40% to 50%. And for advanced liver cancer is the lack of effective treatment, a variety of treatments for advanced liver cancer prolonged survival is not obvious. Therefore, in clinical practice, to find effective ways to extend the treatment of advanced liver cancer survival in patients with hepatocellular carcinoma has important significance. Objective: To investigate intervention in patients with primary liver cancer medicine treatment effect on survival. Methods: A retrospective analysis of Beijing University of Chinese Medicine Hospital East Hospital from 2002 to 2007, patients with liver cancer since the clinical data of 64 cases (55 cases among males, 9 females), by telephone or by way of follow-up petition , as of the date of March 1, 2008. Collected each case syndromes (spleen deficiency, qi stagnation, blood stasis, yin deficiency type, damp-heat) and liver cancer stage (Ⅰ stage, Ⅱ a stage and stage Ⅱ b) factors, combined with clinical follow-up survival data calculations period, enter the computer database, using spss13.0 package for data processing. Calculated using the Kaplan-Meier survival and median survival time. Results: 1 to the follow-up period ended, all 64 cases of hepatocellular carcinoma, a total of 48 cases (75%) died, 16 cases extant. Total 1,2,3-year cumulative survival rates were 79.3%, 55.9%, 21.1%, the median survival time was 26 months. Were collected 34 cases of hepatic arterial chemoembolization (TACE) combined traditional Chinese medicine, 30 cases of hepatic artery embolization cases were cumulative survival and median survival statistics and comparisons. 2 TACE combined traditional Chinese medicine group and the TACE group after 1-year, 2-year, 3-year survival rates were 82.3%, 60.9%, 26.4% and 74.5%, 50.9%, 17.0%. Log-rank test P lt; 0.05, statistically significant difference. Both groups, the median survival time was 28 months and 24 months. 3 different liver stages (Ⅰ stage, Ⅱ a stage and stage Ⅱ b) of the cases were divided into hepatic artery chemoembolization combined with traditional Chinese and simple hepatic arterial chemoembolization two groups were compared, suggesting that stage Ⅰ, Ⅱ a liver cancer, hepatic artery chemoembolization Joint Medicines with high cumulative survival and median survival time, and the statistical analysis with significant differences, including differences in stage Ⅰ maximum (P = 0.031), while the cumulative survival rate of liver cancer in stage Ⅱ b no increase, statistical no significant difference. 4 different syndromes (spleen deficiency, qi stagnation, blood stasis, yin deficiency type) of primary liver cancer cases were divided into hepatic artery chemoembolization combined with traditional Chinese and simple hepatic arterial chemoembolization compared the two groups, suggesting that spleen deficiency, qi stagnation, yin hepatic arterial chemoembolization combined traditional Chinese medicine group has a higher cumulative survival rate and median survival time, and the difference was statistically significant (P lt; 0.05), where Qi stagnation, the biggest difference (P = 0.034), while no increase blood stasis survival, no statistically significant difference. Conclusions: 1. Liver xiaozheng medicine decoction can improve postoperative hepatic arterial chemoembolization cumulative survival and prolong survival time of patients. (2) Chinese medicine decoction on liver and xiaozheng TACE postoperative Ⅰ and Ⅱ a cumulative survival rate of liver cancer and survival have improved, but no significant effect on stage Ⅱ b. 3 Liver xiaozheng medicine decoction after hepatic arterial chemoembolization predominant deficiency, qi stagnation and Yin predominant predominant prognosis has improved, based on the type of stasis no significant improvement. 4 Chinese Liver Decoction xiaozheng stage Ⅰ gas stagnation of liver cancer liver cancer survival rate and cumulative effects of the most significant effect.
|